Vitrakvi
E561039
Vitrakvi is a targeted cancer therapy (larotrectinib) used to treat solid tumors that have a specific NTRK gene fusion, regardless of the tumor’s location in the body.
Statements (49)
| Predicate | Object |
|---|---|
| instanceOf |
pharmaceutical drug
ⓘ
targeted cancer therapy ⓘ tyrosine kinase inhibitor ⓘ |
| hasActiveIngredient | larotrectinib NERFINISHED ⓘ |
| hasAdministrationSchedule | twice daily dosing ⓘ |
| hasApprovalType | tumor-agnostic indication ⓘ |
| hasATCCode | L01EX09 NERFINISHED ⓘ |
| hasBlackBoxWarning | neurotoxicity (region-specific, if applicable) ⓘ |
| hasBrandOwner | Bayer NERFINISHED ⓘ |
| hasCoDeveloper | Bayer NERFINISHED ⓘ |
| hasCommonAdverseEffect |
dizziness
ⓘ
fatigue ⓘ increased liver enzymes ⓘ nausea ⓘ vomiting ⓘ |
| hasDeveloper | Loxo Oncology NERFINISHED ⓘ |
| hasDosageForm |
capsule
ⓘ
oral solution ⓘ |
| hasDrugInteraction |
strong CYP3A4 inducers
ⓘ
strong CYP3A4 inhibitors ⓘ |
| hasFirstApprovalYear | 2018 ⓘ |
| hasIndication |
treatment of metastatic NTRK gene fusion–positive solid tumors
ⓘ
treatment of unresectable NTRK gene fusion–positive solid tumors ⓘ |
| hasInternationalNonproprietaryName | larotrectinib NERFINISHED ⓘ |
| hasMechanismOfAction | selective TRK inhibitor ⓘ |
| hasMolecularTarget | tropomyosin receptor kinases ⓘ |
| hasPediatricUse | yes ⓘ |
| hasPregnancyCategory | may cause fetal harm ⓘ |
| hasRegulatoryApproval |
European Medicines Agency
NERFINISHED
ⓘ
U.S. Food and Drug Administration NERFINISHED ⓘ |
| hasRouteOfAdministration | oral ⓘ |
| hasSelectivity | highly selective for TRK proteins ⓘ |
| isIndicatedWhen |
disease has progressed following prior treatment
ⓘ
no satisfactory alternative treatment options ⓘ |
| isMetabolizedBy | CYP3A4 NERFINISHED ⓘ |
| isOralMedication | true ⓘ |
| isTumorAgnostic | true ⓘ |
| isUsedIn | precision oncology ⓘ |
| requiresDiagnosticTest | NTRK gene fusion testing ⓘ |
| targets |
TRKA
NERFINISHED
ⓘ
TRKB NERFINISHED ⓘ TRKC NERFINISHED ⓘ |
| targetsGeneFusion |
NTRK1
NERFINISHED
ⓘ
NTRK2 NERFINISHED ⓘ NTRK3 ⓘ |
| treats |
adult patients with NTRK gene fusion–positive solid tumors
ⓘ
pediatric patients with NTRK gene fusion–positive solid tumors ⓘ solid tumors with NTRK gene fusion ⓘ |
| wasFirstApprovedIn | United States NERFINISHED ⓘ |
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject surface form:
Loxo Oncology